Skip to Content

Genenta presents company’s pipeline and the preliminary clinical data from Phase I/II in patients affected with glioblastoma multiforme at the Advanced Therapies Congress & Expo 2020

Sep 30, 2020
MILAN (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that it will present new preliminary data from the Phase I/II TEM-GBM study of TemferonTM in patients affected with glioblastoma multiforme, at the 4th Virtual Annual Genetic Medicines Conference, hosted by Chardan on 5th and 6th of October 2020. Pierluigi Paracchi, Chairman and Chief Executive Officer at Genenta Science and Dr. Carlo Russo, Chief Medical Officer and Head of Development, will present the data along with an overview of the company’s pipeline and development of Temferon™ in two solid tumor indications. Presentation Details: Date: Tuesday, October 6 Time (EDT): starting from 2:30pm Registration at: